Related Experiment Video
Updated: Apr 28, 2026

09:12
Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
Published on: April 5, 2024
5.1K
Gene transfer properties and structural modeling of human stem cell-derived AAV
Laura J Smith1, Taihra Ul-Hasan1, Sarah K Carvaines1
1AAV Laboratory, Department of Virology, Beckman Research Institute of City of Hope, Duarte, California, USA.
Summary
Novel adeno-associated virus (AAV) variants were discovered in human stem cells. These AAVHSCs show superior gene transfer efficiency in hematopoietic stem cells (HSCs) for potential therapeutic applications.
Area of Science:
- Gene therapy
- Virology
- Hematopoietic stem cell biology
Background:
- Adeno-associated virus (AAV) vectors are widely used for in vivo gene delivery.
- Previous studies suggested the presence of AAV in human bone marrow.
Purpose of the Study:
- To investigate the presence of natural AAV in CD34(+) hematopoietic stem cells (HSCs).
- To evaluate the potential of novel AAV variants for HSC gene transfer.
Main Methods:
- Isolation and characterization of AAV from human CD34(+) peripheral blood stem cells.
- Generation of gene transfer vectors from novel AAV variants.
- Assessment of gene transfer efficiency and long-term engraftment in human HSCs and xenograft models.
Main Results:
- Novel AAV variants, belonging to AAV Clade F, were identified in healthy CD34(+) HSCs.
- Vectors derived from these AAVs demonstrated superior gene transfer and stable expression in human HSCs compared to other serotypes.
- Transduced HSCs engrafted in vivo, producing differentiated transgene-expressing progeny and persisting long-term, indicating transduction of primitive progenitors.
Conclusions:
- AAVHSCs represent a new class of genetic vectors with significant potential for HSC genome manipulation.
- Identification of capsid components crucial for HSC transduction was achieved through structure-function correlation.
- These findings pave the way for advanced gene therapy strategies targeting HSCs.

